•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Traders are watching several health care stocks after momentum indicators signaled potential oversold conditions, with RSI readings below 30 cited alongside recent price declines and analyst or company updates.
The RSI is a momentum indicator that compares a stock’s strength on days when prices go up to its strength on days when prices go down. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
On April 16, Wedbush analyst David Nierengarten maintained an Outperform rating on Kiniksa Pharmaceuticals and raised the price target from $53 to $58. Over the last five days, the stock fell about 10% and has a 52-week low of $19.62. The RSI value was reported at 28.
Price action: Shares fell 5.4% to close at $42.46 on Monday.
Edge stock ratings: 86.15 momentum score, with value at 49.18.
On April 20, Nano-X Imaging reported worse-than-expected Q4 results. The company said 2025 Q4 showed momentum across all Nano-X business segments, along with commercial progress in the U.S. market. The stock fell about 12% over the last five days and has a 52-week low of $2.11. The RSI value was reported at 28.2.
Price action: Shares fell 24.4% to close at $2.16 on Monday.
Benzinga Pro’s charting tool was cited as helping identify the trend in NNOX stock.
On April 20, Atrium Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The stock was reported to be down around 3% year-to-date and to have a 52-week low of $11.95. The RSI value was reported at 28.4.
Price action: Shares fell 0.8% to close at $14.30 on Monday.
Benzinga Pro’s signals feature was cited as notifying of a potential breakout in RNA shares.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
